Evaluation of New Prognostic Staging Systems (SLiDe score) for Hepatocellular Carcinoma Patients who Underwent Hepatectomy

Background/Aims: A new prognostic staging system, the SLiDe (S, stage; Li, liver damage; De, des-gamma-carboxy prothrombin) score was recently proposed. We examined 207 HCC patients following hepatic resection to determine the usefulness of this staging system for HCC patients after surgery. Methodology: Disease-free and overall survival rates were calculated according to the Kaplan-Meier method, and differences between groups were tested for significance using the log-rank test. Results: Regarding disease-free survival, there were no significant differences in survival between SLiDe score 0 us 1, between score 2 us 3, and between score 4 us 5. There were significant differences between 0-1 us 2-3 (p<0.01) and between 2-3 us 4-5 (p<0.01). Regarding overall survival, there were no significant differences in survival between score 0 us 1, between score 2 us 3, and between score 4 us 5. There were significant differences between 0-1 us 2-3 (p<0.05) and between 2-3 us 4-5 (p<0.01). Conclusions: The SLiDe score, a staging system that combines tumor factors, a tumor marker and hepatic function, might be a better predictor of prognosis in HCC patients who have undergone hepatic resection.